Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) have received an average rating of “Moderate Buy” from the six brokerages that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $9.75.

A number of equities research analysts have commented on the stock. HC Wainwright reissued a “buy” rating and issued a $16.00 price objective on shares of Aclaris Therapeutics in a research report on Monday, October 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aclaris Therapeutics in a research note on Monday.

Institutional Investors Weigh In On Aclaris Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Invesco Ltd. boosted its holdings in Aclaris Therapeutics by 409.0% in the first quarter. Invesco Ltd. now owns 57,079 shares of the biotechnology company’s stock valued at $87,000 after purchasing an additional 45,864 shares in the last quarter. HighTower Advisors LLC lifted its position in shares of Aclaris Therapeutics by 20.2% during the 1st quarter. HighTower Advisors LLC now owns 316,064 shares of the biotechnology company’s stock worth $484,000 after buying an additional 53,116 shares during the last quarter. Algert Global LLC acquired a new position in shares of Aclaris Therapeutics in the 1st quarter valued at $61,000. OMERS ADMINISTRATION Corp boosted its holdings in shares of Aclaris Therapeutics by 223.3% in the 1st quarter. OMERS ADMINISTRATION Corp now owns 175,900 shares of the biotechnology company’s stock valued at $269,000 after buying an additional 121,500 shares in the last quarter. Finally, State of Wyoming purchased a new position in shares of Aclaris Therapeutics in the 1st quarter valued at $72,000. Institutional investors and hedge funds own 98.34% of the company’s stock.

Aclaris Therapeutics Price Performance

ACRS stock opened at $2.78 on Thursday. The business’s 50-day moving average is $2.27 and its two-hundred day moving average is $1.86. The firm has a market capitalization of $301.20 million, a P/E ratio of -2.01 and a beta of 0.62. Aclaris Therapeutics has a 1 year low of $1.05 and a 1 year high of $4.05.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings data on Thursday, November 6th. The biotechnology company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.01. The business had revenue of $3.30 million during the quarter, compared to the consensus estimate of $1.59 million. Aclaris Therapeutics had a negative return on equity of 39.73% and a negative net margin of 900.01%. On average, analysts expect that Aclaris Therapeutics will post -0.82 EPS for the current year.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.